PDCD1 and neoplasm: This may stimulate type 1 conventional dendritic cells (cDC1) and CD8 + T cells, allowing for tumor control.[19] SMAD4 mutations may cause smad4 deficiency, and SMAD4 deficiency might increase the immune prototype, leading to an extended response to PD-1 blockade.